Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this research study is to determine the diurnal and nocturnal effects of Travoprost with SofZia (Travatan Z) on intraocular pressure and ocular perfusion pressure.
Condition or disease
Open Angle GlaucomaOcular Hypertension
The investigators hypothesize that Travatan Z will significantly lower intraocular pressure and increase ocular perfusion pressure during both the diurnal and nocturnal period, during a 24-hour evaluation, compared to baseline. The investigators further hypothesize that the medication effects will persist at 72 hours after discontinuation of the drug.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 90 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients diagnosed with open angle glaucoma or ocular hypertension
Diagnosis of open-angle glaucoma or ocular hypertension, including pigment dispersion glaucoma and pseudoexfoliation glaucoma
Age ≥ 18 or ≤ 90 years, of either gender, or any race/ethnicity
Females who are currently pregnant or planning to become pregnant, as determined by history during the study period
Diagnosis of any other form of glaucoma other than open-angle
Schaffer angle grade < 2 in either eye by gonioscopy
Chronic, recurrent, or severe inflammatory eye disease
Intraocular surgery within 6 months or laser within 3 months
History of active, recurrent, or chronic ocular infection with the Herpes Simplex Virus
History of cystoid macular edema
Inability to safely discontinue all ocular medications for 4 weeks
Patients who smoke or have irregular daily sleep patterns
Patients who have started or changed glucocorticoids therapy in the last 3 months
Patients who are currently undergoing medical marijuana therapy
Any use of a non-FDA approved medication for glaucoma in the last 3 months